Warning Letters 2014
These letters are supplied by the CDER Freedom of Electronic Information Office. This page only covers Office of Prescription Drug Promotion (formerly Division of Drug Marketing, Advertising and Communications) and CDER Headquarters Warning Letters.
- Office of Prescription Drug Promotion Letters
- Office of Compliance/Immediate Office
- Office of Drug Security, Integrity and Recalls
For District Office Warning Letters see the Main FDA FOI Warning Letters Page. Some of the letters have been redacted or edited to remove confidential information. Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter. If you wish to obtain available additional information on the current status of an issue in a particular warning letter or notice of violation on this website, please contact the Agency or the recipient of the letter directly. Inquiries to FDA should be sent to:
Food and Drug Administration
Freedom of Information Staff (HFI-35)
5600 Fishers Lane, Rockville, MD 20857
Instructions for how to submit an FOI request can be found on the FDA FOI Page.
Mission Pharmaceutical Company
|NDA 021618 Tindamax (tinidazole) tablets for oral use||1/24/14|
|Regulations for finished pharmaceuticals||2/6/2014|
|Labeling/relabeling of active pharmaceutical ingredients (APIs)||1/31/2014|